| Post | Subject | | |
#216
0
|
12/12 MannKind Guidance Will Apparently Be As Clear
|
TREND1
| 12/12/17 11:16:26 AM |
|
#215
0
|
12/8 Spencer Osborne's Blog
|
TREND1
| 12/08/17 06:43:14 PM |
|
#214
0
|
12/6 Spencer Osborne's Blog
|
TREND1
| 12/06/17 12:18:56 PM |
|
#213
0
|
12/2 MannKind's Afrezza Scripts Dip On Holiday Week
|
TREND1
| 12/02/17 11:26:34 AM |
|
#212
0
|
12/1 MannKind - Setting The Record Straight
|
TREND1
| 12/02/17 11:24:31 AM |
|
#211
0
|
11/30 MannKind - Technical Look
|
TREND1
| 11/30/17 12:09:46 PM |
|
#210
0
|
11/30 Could The FDA's Less Stringent Regulations Help MannKind?
|
TREND1
| 11/30/17 12:07:01 PM |
|
#209
0
|
11/23 An Integrated BioSci Research On MannKind Corporation:
|
TREND1
| 11/23/17 12:45:39 PM |
|
#208
0
|
11/21 Exact Sciences, We Bid You Farewell
|
TREND1
| 11/21/17 10:46:40 AM |
|
#207
0
|
11/20 Enanta Pharmaceuticals' (ENTA) CEO Jay Luly on
|
TREND1
| 11/20/17 10:31:11 PM |
|
#206
0
|
11/20 Enanta Pharma misses by $0.27, beats on revenue
|
TREND1
| 11/20/17 05:22:30 PM |
|
#205
0
|
11/20 MannKind And Guidance
|
TREND1
| 11/20/17 12:23:41 PM |
|
#204
0
|
11/18 Exact Science: 40% Market Share?
|
TREND1
| 11/18/17 12:21:53 PM |
|
#203
0
|
11/17 EXACT Sciences (EXAS) Presents At Jefferies 2017
|
TREND1
| 11/17/17 01:36:22 PM |
|
#202
0
|
11/16 MannKind: Insider Trading, Short Interest, And Catalysts,
|
TREND1
| 11/16/17 03:03:30 PM |
|
#201
0
|
11/14 Spencer Osborne's Blog Growth, value, special situations, momentum
|
TREND1
| 11/14/17 04:09:12 PM |
|
#200
0
|
11/14 EXACT Sciences (EXAS) Q3 2017 Results -
|
TREND1
| 11/14/17 01:09:13 PM |
|
#199
0
|
11/3 MannKind - Deferred Revenue, Revenue, And Cash
|
TREND1
| 11/13/17 11:28:26 AM |
|
#198
0
|
11/10 MannKind - Afrezza Scripts And The Special Meeting
|
TREND1
| 11/11/17 03:42:10 PM |
|
#197
0
|
11/8 MannKind Q3 Call - The Good, The
|
TREND1
| 11/08/17 05:53:01 PM |
|
#196
0
|
11/7 MannKind Earnings On Tap - What We
|
TREND1
| 11/07/17 02:46:19 PM |
|
#195
0
|
11/6 MannKind Scripts Rebound - Why The Equity
|
TREND1
| 11/06/17 10:35:16 AM |
|
#194
0
|
10/31 MannKind Isurance Update
|
TREND1
| 10/31/17 01:25:49 PM |
|
#193
0
|
10/30 MannKind: Afrezza Scripts Flat Into Q2
|
TREND1
| 10/30/17 02:47:41 PM |
|
#192
0
|
10/24 MannKind: Debt Holders Are Bullish
|
TREND1
| 10/24/17 01:27:05 PM |
|
#191
0
|
10/23 MannKind: The Proof Is In The Pie
|
TREND1
| 10/23/17 06:01:04 PM |
|
#190
0
|
10/20 With Afrezza Sales Flat, MannKind Needs Growth
|
TREND1
| 10/20/17 07:40:10 PM |
|
#189
0
|
10/16 MannKind - Script Sales Dip To Start Q4
|
TREND1
| 10/16/17 10:35:24 AM |
|
#188
0
|
10/10 MannKind Is A Trade Not An
|
TREND1
| 10/10/17 01:27:06 PM |
|
#186
0
|
10/9 MannKind: Rise On Affreza Label Revision Acceptance
|
TREND1
| 10/09/17 10:24:58 AM |
|
#185
0
|
10/8 MannKind - Warrant Exchange Contract
|
TREND1
| 10/08/17 09:21:50 PM |
|
#184
0
|
10/6 CHART OF ACC NEW SCRIPTS VS REFILLS
|
TREND1
| 10/06/17 12:43:15 PM |
|
#183
0
|
10/6 MannKind Is In A Race It Can't Win
|
TREND1
| 10/06/17 12:07:57 PM |
|
#182
0
|
MNKD
|
TREND1
| 10/05/17 09:36:31 PM |
|
#176
0
|
10/3 MU
|
TREND1
| 10/03/17 03:55:38 PM |
|
#175
0
|
10/2 Micron: The Endorsement Of An Icon
|
TREND1
| 10/03/17 03:30:48 PM |
|
#174
0
|
10/2 Afrezza Gets Label Change - Is It
|
TREND1
| 10/03/17 10:41:56 AM |
|
#173
0
|
10/1 MannKind Corporation to Hold Investor Conference Call
|
TREND1
| 10/01/17 11:12:37 PM |
|
#172
0
|
MNKD 10 MIN
|
TREND1
| 09/28/17 09:15:15 PM |
|
#171
0
|
9/27 MannKind: FDA Label Decision Is Almost Here
|
TREND1
| 09/27/17 11:04:12 AM |
|
#170
0
|
9/22 MannKind: Afrezza Scripts Rebound To Highest Level
|
TREND1
| 09/22/17 05:23:41 PM |
|
#169
0
|
9/14 MannKind Puts Focus On Pipeline
|
TREND1
| 09/14/17 12:28:32 PM |
|
#168
0
|
9/13 MannKind: Their Technosphere Drug Delivery System -
|
TREND1
| 09/13/17 11:18:29 AM |
|
#167
0
|
9/11 MannKind Corporation's (MNKD) CEO Michael Castagna Presents
|
TREND1
| 09/11/17 06:50:15 PM |
|
#166
0
|
9/9 MannKind - Afrezza Scripts Finish August Flat
|
TREND1
| 09/09/17 11:34:15 AM |
|
#165
0
|
9/1 MannKind: Afrezza Sales Bring In More Dollars;
|
TREND1
| 09/01/17 03:11:52 PM |
|
#164
0
|
8/25 MannKind - Scripts, Marketing, And Clinical Trials
|
TREND1
| 08/25/17 04:11:29 PM |
|
#163
0
|
8/18 MannKind - Scripts Rise, But Not Enough
|
TREND1
| 08/18/17 01:02:53 PM |
|
#162
0
|
8/8 Micron Technology Is Looking Cheap
|
TREND1
| 08/08/17 11:27:06 AM |
|
#161
0
|
8/8 MannKind's (MNKD) CEO Michael Castagna On Q2
|
TREND1
| 08/08/17 11:24:54 AM |
| Post | Subject | | |